| Identification | Back Directory | [Name]
4(1H)-Quinolinone, 1-ethyl-3-[[(3R)-3-[[(2S)-2-hydroxy-3-[3-(methylsulfonyl)phenoxy]propyl]amino]-1-oxa-8-azaspiro[4.5]dec-8-yl]sulfonyl]- | [CAS]
2169905-68-2 | [Synonyms]
4(1H)-Quinolinone, 1-ethyl-3-[[(3R)-3-[[(2S)-2-hydroxy-3-[3-(methylsulfonyl)phenoxy]propyl]amino]-1-oxa-8-azaspiro[4.5]dec-8-yl]sulfonyl]- | [Molecular Formula]
C29H37N3O8S2 | [MOL File]
2169905-68-2.mol | [Molecular Weight]
619.75 |
| Chemical Properties | Back Directory | [Boiling point ]
851.6±75.0 °C(Predicted) | [density ]
1.44±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
13.70±0.20(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Description]
Vemtoberant, also known as APD418, is a β3-adrenergic receptor (AdrR) antagonist for treatment of decompensated heart failure. Unlike current inotrope therapie , Vemtoberant improves cardiac contractility with minimal negative impact on heart rate, blood pressure, and myocardial oxygen consumption. Vemtoberant has undergone Phase 2 trials for those in heart failure with reduced ejection fraction. | [Uses]
Vemtoberant is an β3 Adrenergic Receptor antagonist. Vemtoberant can be used for research of β3 adrenergic receptor-mediated disorder, such as, heart failure[1][2]. | [References]
[1] WHO Drug Information-World Health Organization (WHO).
[2] Tran Thuy-Anh, et al. Preparation of modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto: World Intellectual Property Organization, WO2017214002. 2017-12-14. |
|
|